
Kengo Akashi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4927966/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids. Rheumatology International, 2022, 42, 1403-1409.	3.0	9
2	Identification of plexin D1 on circulating extracellular vesicles as a potential biomarker of polymyositis and dermatomyositis. Rheumatology, 2022, 61, 1669-1679.	1.9	4
3	The real-world effectiveness of anti-RANKL antibody denosumab on the clinical fracture prevention in patients with rheumatoid arthritis: The ANSWER cohort study. Modern Rheumatology, 2022, 32, 834-838.	1.8	4
4	Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study. Rheumatology International, 2022, 42, 1227-1234.	3.0	8
5	Pressure Ulcer in Three Cases of Anit-MDA5 Antibody Positive Dermatomyositis. Nishinihon Journal of Dermatology, 2022, 84, 121-125.	0.0	0
6	Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study. Rheumatology International, 2020, 40, 1987-1995.	3.0	11
7	Subjective wellâ€being among rheumatoid arthritis patients. International Journal of Rheumatic Diseases, 2019, 22, 1863-1870.	1.9	5
8	Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. Arthritis Research and Therapy, 2018, 20, 165.	3.5	33
9	Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study PLoS ONE, 2018, 13, e0194130.	2.5	65